Industry Needs To Emphasize Drug Benefits In Response To Risk Concerns, Wyeth Exec Says
This article was originally published in The Pink Sheet Daily
The pharma industry has become over-regulated, Wyeth R&D head Ruffolo says.
You may also be interested in...
Deputy commissioner says “institutional protections” and “decision-making based on past principle” ensure review process is not overly influenced by external pressures.
HAMBURG, Germany - Due to the increasingly global nature of biotechnology, the Biotechnology Industry Organization's board of directors will meet next month to discuss a proposal to expand its global reach and potentially create a department of international relations, BIO President Jim Greenwood said Nov. 13